BofA raised the firm’s price target on Ascendis Pharma (ASND) to $260 from $246 and keeps a Buy rating on the shares as part of the firm’s Q4 small-to-mid cap biotech earnings preview.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ASND:
- Ascendis Pharma initiated with an Overweight at Barclays
- Looking for Exposure to UnitedHealth Stock (UNH) ahead of Q4 Earnings? Here’s How to Buy Without the Risk
- Ascendis Pharma rumor highlighted in Betaville blog
- Ascendis Pharma price target raised to $250 from $245 at RBC Capital
- Ascendis Pharma price target raised to $330 from $322 at Wells Fargo